Stock Ratings / Health Care / TXMD / financials

BYSI (42) AYTU (41) QNTM (58) ACTU (43) ⌘ Pro Terminal →

TherapeuticsMD Inc. (TXMD) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.83 +2.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

TherapeuticsMD Inc. (TXMD) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $21.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-4.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TXMD)Realized 20D OHLCV Swing Band: ±7.2%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How TXMD Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$593.1K (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $1.3M

FY24

Rev $1.8M

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-0.1%	-$569.0K	-$540.5K	-12.9%
FY 2024	$1.8M	52%	-80%	-$2.2M	-$2.1M	-21.6%
FY 2023	$1.3M	52%	-80%	-$10.3M	-$9.8M	-12.9%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TXMD)

✓Walkthrough of TXMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TXMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -10.29%▼ DESCENDING CHANNEL

2026-10-30O $1.80H $1.83L $1.80C $1.83VOL 3.8K

RES: $2.23SUP: $1.70SMA50: $2.05SMA200: $2.12

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TXMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TXMD Butterfly Map → + Track TXMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TXMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TXMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TXMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TXMD)

Health Care Rank #391 of 1016 ⚔️ BYSI vs TXMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TXMD vs. BYSI, AYTU, QNTM, ACTU)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, TherapeuticsMD Inc. (TXMD) ranks #391 by composite RQD confidence (48/100, grade D) and #828 by equity capitalization ($21.2M). Within this direct 5-issuer industry benchmark cohort, TXMD leads on earnings valuation at N/A trailing P/E, while TXMD leads on capital efficiency and profitability with -12.9% ROIC and — gross margin. QNTM currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with TXMD at 48/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TXMD ACTIVE TherapeuticsMD Inc.	D	48/100	—	—	-12.9%	+2.24%	$21.2M	Benchmark Subject
BYSI BeyondSpring Inc.	D-	42/100	—	—	-35.0%	-1.49%	$21.2M	/bysi-vs-txmd →
AYTU Aytu BioPharma Inc.	D-	41/100	—	69.0%	-35.0%	+0.51%	$21.5M	/aytu-vs-txmd →
QNTM Quantum Biopharma Ltd. Class B Subordinate Voting Shares	D+	58/100	—	—	—	+2.95%	$20.7M	/qntm-vs-txmd →
ACTU Actuate Therapeutics Inc.	D-	43/100	—	—	-35.0%	-3.21%	$20.4M	/actu-vs-txmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000025743

In its most recent audited fiscal period (FY2025, filed 2025-12-31), TherapeuticsMD Inc. (TXMD) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $1.8M , and -100.0% cumulative change since FY2023) , GAAP net income of -$569.0K, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, TXMD closed FY2025 with $37.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$569.0K	—	—	$37.7M	—
FY2024 (FY)	2024-12-31	$1.8M	-$2.2M	—	—	$38.8M	—
FY2023 (FY)	2023-12-31	$1.3M	-$10.3M	—	—	—	—

3. TXMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TXMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, TherapeuticsMD Inc. (NASDAQ: TXMD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $1.83 (+2.24% 1D, market cap $21.2M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TXMD ranks #391 in composite RQD confidence.

How does TXMD compare to BYSI and AYTU in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TXMD carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -12.9%. By comparison, BYSI (BeyondSpring Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $21.2M) and AYTU (Aytu BioPharma Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $21.5M). Among the 5-stock peer group, TXMD leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TXMD?

Per TXMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000025743), TherapeuticsMD Inc. generated $0 in revenue (-100.0% YoY), -$569.0K in net income, and $0 in free cash flow against $37.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TXMD trading relative to its 50-day, 200-day, and 52-week technical levels?

TXMD last traded at $1.83 (+2.24% on volume of 4,285 shares), positioning the stock -10.73% below its 50-day simple moving average ($2.05) and -13.68% below its 200-day simple moving average ($2.12). Across its 52-week range of $1.11 to $2.95, TXMD sits at the 39.1% percentile with a 14-day RSI of 33.3 (NEUTRAL RANGE) and an implied next-earnings move of ±7.2% ($1.70 to $1.96).